Oncology

Blocking the recruitment of blood vessels suppresses small cell lung cancer tumor growth.

Consuming 2.5 servings of coffee per day found to decrease colorectal cancer development by up to 50%.

Top news of the day from across the health care landscape.

Afatinib (Gilotrif) shows significant improvements in overall survival and disease progression.

New technique offers sustained release of antibodies directly to skin cancer tumor.

Afatinib (Gilotrif) shows significant improvements in overall survival and disease progression.

Recent advances and updates in oncology and cancer drug development.

Sulindac and erlotinib effectively reduced the total duodenal polyps in patients with familial adenomatous polyposis.

Sugary drinks found to triple the risk of developing prostate cancer.

A new study shows that genes can become sensitive to crizotinib after the introduction of ponatinib.

Top news of the day from across the health care landscape.

Dietary intake of methionine and tryptophan may slow brain cancer tumor progression.

Single-cell method identifies core stem cells that cause leukemia within a tumor.

Ruptured cancerous cells are able to repair themselves to prevent cell death.

Study finds need for improved understanding of the association between rising systemic therapy use and the uptake of palliative care.

Cancer’s long-term side effects on fertility should be discussed with parents of young cancer patients.

Top news of the day from across the health care landscape.

Avella Specialty Pharmacy has launched two innovative apps to help providers select the most appropriate specialty drug options for hepatitis C and oncology patients.

Medical androgen deprivation therapies combined with other treatments may cause relapse in patients with prostate cancer.

Inhibiting GCN5 enzyme may lead to reduced remission risks and improved cure rates.

While PSA levels decreased in patients, overall survival did not improve in patients with non-metastatic prostate cancer.

New system could lead to advances in cancer investigation and drug discovery.

Venetoclax (Venclexta)is the first treatment approved by the FDA that inhibits the B-cell lymphoma 2 (BCL-2) protein.

A flood of new therapies approved last year offer new hope for patients with multiple myeloma.

New technique allows physicians to see if a tumor is susceptible or resistant to treatment much earlier than conventional methods.

Atezolizumab treats locally advanced or metastatic NSCLC expressing the PD-L1 protein.

Top news of the day across the health care landscape.

Atezolizumab was previously granted Breakthrough Therapy Designation for NSCLC in February 2015.

Low oxygen conditions encourage some cancer stem cells to multiply.

Recent advances and updates in oncology and cancer drug development.